Enhanced tumor immunogenicity through coupling cytokine expression with antigen presentation.

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Cytotoxic T cell (CTL) function is crucial for antitumor immune responses and relies on tumor antigen and MHC class I molecule presentation.
• Enhancing antigen expression and presentation can improve the efficacy of cancer immunotherapies.

Purpose of the Study:

• To investigate the feasibility of modifying a cytokine signal peptide with a tumor antigenic epitope.
• To assess if modified signal peptides retain functionality and enhance tumor cell immunogenicity.

Main Methods:

• Genes encoding MHC class I-restricted antigenic epitopes (chicken ovalbumin and tyrosinase-related protein 2) were inserted into the interleukin-2 signal sequence.
• The functionality of modified signal peptides was assessed by measuring cytokine secretion.
• Tumor cell immunogenicity was evaluated through in vitro CTL lysis assays and in vivo tumor growth studies.

Main Results:

• Modified signal peptides retained their function, enabling cytokine secretion.
• The incorporated antigenic epitopes were processed and presented on the tumor cell surface.
• Gene-modified tumor cells showed increased susceptibility to CTL lysis and reduced tumor growth in vivo.

Conclusions:

• Modifying cytokine signal peptides with tumor antigenic epitopes is feasible and enhances tumor cell immunogenicity.
• This strategy shows potential for improving cancer immuno-gene therapy and vaccine development.
• The findings offer new perspectives for designing therapeutic strategies against cancer.